Replimune Group Inc (REPL)
Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).
REPL SEC Filing Email Alerts Service
Company Name: |
Replimune Group Inc |
Website: |
www.replimune.com |
Sector: |
Biotechnology |
Number of ETFs Holding REPL: |
23 |
Total Market Value Held by ETFs: |
$74.03M |
Total Market Capitalization: |
$439.00M |
% of Market Cap. Held by ETFs: |
16.86% |
|
|
April 18, 2024 6:09 PM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|